Political Economy Analysis and the Aid Industry: The Road to Nowhere?

Political-economy analysis has been a favourite instrument among donors of development aid since roughly the turn of the century. The usefulness of such forms of analysis has been emphasised because donors realised that their focus on formal aspects of the social and political organisation of countries caused them to overlook important elements of the ‘political economy’ of these countries. As a result of this, political and governance reform programmes, which had become part and parcel of the agenda of development under the Post-Washington Consensus, turned out to be much less effective than anticipated. The call for donor agencies to ‘look behind the façade’ of formal institutions in developing countries has thus come as part of the aid effectiveness agenda. It was argued that the effectiveness of development assistance policies would be enhanced if the realities of social and political power structures in developing countries were mapped and fed into the design of governance reforms targeting those countries. A more or less tacit assumption in this approach was that political-economy analysis would enable donors to identify potential pockets of resistance against the reforms that donors were advocating – hence improving the chances of getting reforms accepted

Unified dark energy models : a phenomenological approach

A phenomenological approach is proposed to the problem of universe accelerated expansion and of the dark energy nature. A general class of models is introduced whose energy density depends on the redshift $z$ in such a way that a smooth transition among the three main phases of the universe evolution (radiation era, matter domination, asymptotical de Sitter state) is naturally achieved. We use the estimated age of the universe, the Hubble diagram of Type Ia Supernovae and the angular size - redshift relation for compact and ultracompact radio structures to test whether the model is in agreement with astrophysical observation and to constrain its main parameters. Although phenomenologically motivated, the model may be straightforwardly interpreted as a two fluids scenario in which the quintessence is generated by a suitably chosen scalar field potential. On the other hand, the same model may also be read in the context of unified dark energy models or in the framework of modified Friedmann equation theories.Comment: 12 pages, 10 figures, accepted for publication on Physical Review

Diagnosis and management of Guillain–Barré syndrome in ten steps

Guillain–Barré syndrome (GBS) is a rare, but potentially fatal, immune-mediated disease of the peripheral nerves and nerve roots that is usually triggered by infections. The incidence of GBS can therefore increase during outbreaks of infectious diseases, as was seen during the Zika virus epidemics in 2013 in French Polynesia and 2015 in Latin America. Diagnosis and management of GBS can be complicated as its clinical presentation and disease course are heterogeneous, and no international clinical guidelines are currently available. To support clinicians, especially in the context of an outbreak, we have developed a globally applicable guideline for the diagnosis and management of GBS. The guideline is based on current literature and expert consensus, and has a ten-step structure to facilitate its use in clinical practice. We first provide an introduction to the diagnostic criteria, clinical variants and differential diagnoses of GBS. The ten steps then cover early recognition and diagnosis of GBS, admission to the intensive care unit, treatment indication and selection, monitoring and treatment of disease progression, prediction of clinical course and outcome, and management of complications and sequelae

Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study

Brain-derived neurotrophic factor (BDNF) has the theoretical potential to protect neurones from axonal degeneration. The objective of this study was to discover whether brain-derived neurotrophic factor is safe in Guillain-Barré syndrome, and to make preliminary observations of its efficacy. This was a parallel group randomized controlled trial of subcutaneous brain-derived neurotrophic factor 25 µ/kg daily compared with placebo for up to 24 weeks or until patients could walk without aid. Six patients received brain-derived neurotrophic factor, of whom three had serious adverse events including one death. Four patients received placebo, of whom two had serious adverse events including one death. The rate and extent of recovery were similar in the two groups. This pilot study did not detect any serious adverse events attributed to brain-derived neurotrophic factor treatment